Abbvie Inc patents expiration
1. Mavyret patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8648037 | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(8 years from now) | |
| US8937150 | ABBVIE INC | Anti-viral compounds |
May, 2032
(8 years from now) | |
| USRE48923 | ABBVIE INC | Crystal forms |
May, 2035
(11 years from now) | |
| US9321807 | ABBVIE INC | Crystal forms |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039754 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US10028937 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9586978 | ABBVIE INC | Anti-viral compounds |
Nov, 2030
(7 years from now) | |
|
US10039754 (Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(7 years from now) | |
|
US10028937 (Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(7 years from now) | |
|
US9586978 (Pediatric) | ABBVIE INC | Anti-viral compounds |
May, 2031
(7 years from now) | |
|
US8648037 (Pediatric) | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(8 years from now) | |
|
US8937150 (Pediatric) | ABBVIE INC | Anti-viral compounds |
Nov, 2032
(9 years from now) | |
| US11484534 | ABBVIE INC | Methods for treating HCV |
Mar, 2034
(10 years from now) | |
| US10286029 | ABBVIE INC | Method for treating HCV |
Mar, 2034
(10 years from now) | |
|
US11484534 (Pediatric) | ABBVIE INC | Methods for treating HCV |
Sep, 2034
(10 years from now) | |
|
US10286029 (Pediatric) | ABBVIE INC | Method for treating HCV |
Sep, 2034
(10 years from now) | |
|
USRE48923 (Pediatric) | ABBVIE INC | Crystal forms |
Nov, 2035
(12 years from now) | |
|
US9321807 (Pediatric) | ABBVIE INC | Crystal forms |
Dec, 2035
(12 years from now) | |
| US11246866 | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(12 years from now) | |
|
US11246866 (Pediatric) | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
| M (M) | Apr 10, 2023 |
| Pediatric Exclusivity (PED) | Dec 10, 2028 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
Market Authorisation Date: 03 August, 2017
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv)...
Dosage: TABLET;ORAL
MAVYRET family patents
2. Oriahnn (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7419983 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(9 months from now) | |
| US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11459305 | ABBVIE INC | Processes for the preparation of uracil derivatives |
Nov, 2028
(5 years from now) | |
| US10881659 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(10 years from now) | |
| US11045470 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
| New Product (NP) | May 29, 2023 |
NCE-1 date: 2022-07-23
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
Dosage: CAPSULE;ORAL
ORIAHNN (COPACKAGED) family patents
3. Orilissa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7419983 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(9 months from now) | |
| US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7176211 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(9 months from now) | |
| US11344551 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(10 years from now) | |
| US10682351 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(12 years from now) | |
| US10537572 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 2022-07-23
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to r...
Dosage: TABLET;ORAL
ORILISSA family patents
4. Qulipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US8754096 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
| US9850246 | ABBVIE INC | Process for making CGRP receptor antagonists |
Mar, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117836 | ABBVIE INC | Tablet formulation for CGRP active compounds |
Jan, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Apr 17, 2026 |
| New Chemical Entity Exclusivity (NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 2025-09-28
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of episodic migraine in adults
Dosage: TABLET;ORAL
QULIPTA family patents
5. Rinvoq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47221 | ABBVIE INC | Tricyclic compounds |
Dec, 2030
(7 years from now) | |
| US8962629 | ABBVIE INC | Tricyclic compounds |
Jan, 2031
(7 years from now) | |
| US11186584 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US10981923 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US9951080 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10519164 | ABBVIE INC | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US11198697 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US10730883 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US10344036 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US11365198 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US10202393 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US10995095 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US10597400 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US10550126 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US9963459 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US10981924 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US11512092 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 16, 2024 |
| New Indication (I) | Jan 14, 2025 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 2023-08-17
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults and pediatric patients 12 years of age and older...
Dosage: TABLET, EXTENDED RELEASE;ORAL
RINVOQ family patents
6. Technivie patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(7 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(10 months from now) | |
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(10 months from now) | |
|
US8399015 (Pediatric) | ABBVIE INC | Solid pharmaceutical dosage form |
Feb, 2025
(1 year, 4 months from now) | |
|
US8268349 (Pediatric) | ABBVIE INC | Solid pharmaceutical dosage form |
Feb, 2025
(1 year, 4 months from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(7 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(7 years from now) | |
|
US8420596 (Pediatric) | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Oct, 2031
(8 years from now) | |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir
Dosage: TABLET;ORAL
TECHNIVIE family patents
7. Venclexta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546399 | ABBVIE INC | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(7 years from now) | |
| US10730873 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(8 years from now) | |
| US8722657 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9174982 | ABBVIE INC | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(6 years from now) | |
| US11369599 | ABBVIE INC | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
May, 2032
(8 years from now) | |
| US11413282 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US10993942 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US11110087 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US9539251 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 15, 2026 |
| M (M) | Oct 16, 2023 |
Drugs and Companies using VENETOCLAX ingredient
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnos...
Dosage: TABLET;ORAL
VENCLEXTA family patents
8. Viekira Pak (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE INC | Anti-infective agents and uses thereof |
Dec, 2028
(5 years from now) | |
| US8188104 | ABBVIE INC | Anti-infective agents and uses thereof |
May, 2029
(5 years from now) | |
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(7 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(10 months from now) | |
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(10 months from now) | |
| US9139536 | ABBVIE INC | Anti-infective agents and uses thereof |
Nov, 2028
(5 years from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(7 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(7 years from now) | |
| US8685984 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8492386 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8466159 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8680106 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US10201542 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(10 years from now) | |
| US9629841 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(10 years from now) | |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, riton...
Dosage: TABLET;ORAL
VIEKIRA PAK (COPACKAGED) family patents
9. Viekira Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE INC | Anti-infective agents and uses thereof |
Sep, 2028
(4 years from now) | |
| US8188104 | ABBVIE INC | Anti-infective agents and uses thereof |
May, 2029
(5 years from now) | |
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(7 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(10 months from now) | |
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(10 months from now) | |
| US9139536 | ABBVIE INC | Anti-infective agents and uses thereof |
Nov, 2028
(5 years from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(7 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(7 years from now) | |
| US10201584 | ABBVIE INC | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
| US10201541 | ABBVIE INC | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
| US8466159 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8685984 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8680106 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8492386 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US10105365 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(11 years from now) | |
| US9333204 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(11 years from now) | |
| US9744170 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(11 years from now) | |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprev...
Dosage: TABLET, EXTENDED RELEASE;ORAL
VIEKIRA XR family patents
10. Vuity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610518 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(15 years from now) | |
| US11285134 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule (D) | Mar 28, 2026 |
| New Product (NP) | Oct 28, 2024 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2021
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
VUITY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic